David M. Mott
Chairman
Adaptimmune Therapeutics PLC (ADAPY)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About David M. Mott
David M. Mott is recorded as Chairman at Adaptimmune Therapeutics PLC (ADAPY). Enliven Therapeutics, Inc. reported in an 8-K filed March 1, 2023 that David M. Mott resigned as Board, effective February 23, 2023.
“Pursuant to the Merger Agreement, on February 23, 2023, immediately prior to and effective upon the closing of the Merger, David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Start not stated–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Adaptimmune Therapeutics PLC
Other people whose current roles at this company are on record from its filings.
- Adrian Rawcliffe CEO, Board Member
- Christopher Hill CFO
- William Bertrand COO
- Ali Behbahani Board Member
- Andrew Allen Board Member
- Andrew Allen, MD, PhD Board Member
- Andrew R. Allen Board Member
- Dr Priti Hegde Board Member
- Garry E. Menzel Board Member
- Garry Menzel Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.